Montorsi F, Guazzoni G, Bergamaschi F, Zucconi M, Rigatti P, Pizzini G, Miani A, Pozza G
Institute of Human Anatomy, Scientific Institute H. San Raffaele, Milan, Italy.
Acta Diabetol. 1994 Apr;31(1):1-5. doi: 10.1007/BF00580752.
The aim of this study was to assess the effectiveness and safety of intracavernous injections of a four-drug vasoactive mixture in diabetic patients with organic impotence. A group of 60 diabetic patients with either pure neurogenic, pure vasculogenic or mixed neurovasculogenic impotence were treated with intracavernous injections of a combination of 12.1 mg/ml papaverine hydrochloride, 1.01 mg/ml phentolamine mesylate, 10.1 micrograms/ml prostaglandin E1 and 0.15 mg/ml atropine sulphate ('full-dose' mixture). A mixture of the same drugs but at one-third concentrations ('reduced-dose' mixture) was also used. The mean (+/- SEM) volumes of the full-dose and reduced-dose mixtures used were 0.21 +/- 0.03 ml and 0.31 +/- 0.02 ml, respectively. All the patients were able to sustain a rigid erection at the end of the titration phase of the study. At a mean follow-up of 18 months, 48 patients (80%) were successfully using the mixture, 6 patients (10%) were using the mixture at a dose lower than the initial dose and 6 patients (10%) had dropped out from the injection therapy. No major complications were seen. The association of multiple vasoactive drugs which use different mechanisms of action, thus exerting a pharmacological synergism, is an effective and safe procedure in intracavernous pharmacotherapy for diabetic patients with organic impotence.
本研究的目的是评估海绵体内注射一种四联血管活性混合物对患有器质性阳痿的糖尿病患者的有效性和安全性。一组60例患有单纯神经源性、单纯血管源性或混合性神经血管源性阳痿的糖尿病患者接受了海绵体内注射，注射药物为12.1毫克/毫升盐酸罂粟碱、1.01毫克/毫升甲磺酸酚妥拉明、10.1微克/毫升前列腺素E1和0.15毫克/毫升硫酸阿托品的组合（“全剂量”混合物）。还使用了相同药物但浓度为三分之一的混合物（“减量”混合物）。全剂量和减量混合物的平均（±标准误）使用体积分别为0.21±0.03毫升和0.31±0.02毫升。在研究的滴定阶段结束时，所有患者都能维持阴茎勃起。平均随访18个月时，48例患者（80%）成功使用该混合物，6例患者（10%）以低于初始剂量的剂量使用该混合物，6例患者（10%）退出注射治疗。未观察到重大并发症。多种使用不同作用机制从而发挥药理协同作用的血管活性药物联合应用，对于患有器质性阳痿的糖尿病患者进行海绵体内药物治疗是一种有效且安全的方法。
